ISSN 2412-4036 (print)
ISSN 2713-1823 (online)

The role of esophagoprotection in the treatment of gastroesophageal reflux disease with extraesophageal manifestations

M.A. Livzan, O.V. Gaus

Omsk State Medical University, Omsk, Russian Federation
Abstract. Extraesophageal manifestations of gastroesophageal reflux disease (GERD) – primarily otolaryngological – are widespread in the general population and represent a significant clinical challenge. The aim of the review is to synthesize current scientific literature regarding the pathogenesis, diagnosis, and treatment of laryngopharyngeal symptoms associated with GERD, while also substantiating the role of esophagoprotection in patient management. We examined contemporary conceptions on GERD-associated laryngopharyngeal symptoms and the mechanisms underlying their development, highlighting the pathogenic significance of reduced mucosal resistance in the esophagus and upper respiratory tract. Furthermore, we analyzed the diagnostic capabilities and limitations of existing methods for identifying GERD with extraesophageal manifestations. Also we discussed the advisability for incorporating esophagoprotective agents into standard GERD therapy to improve clinical outcomes, specifically by reducing the risk of disease recurrence and progression.

Keywords

extraesophageal manifestations of gastroesophageal reflux disease
laryngopharyngeal symptoms
laryngopharyngeal reflux
pH-impedance monitoring
pepsin
proton pump inhibitors
prokinetics
esophagoprotective agent

References

  1. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018;67(3):430–40.

    PMID: 28232473. https://doi.org/10.1136/gutjnl-2016-313589

  2. Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro-esophageal reflux disease: A comprehensive review. Dis Esophagus. 2017;30(2):1–9.

    PMID: 27862680. https://doi.org/10.1111/dote.12511

  3. Андреев Д.Н., Маев И.В., Бордин Д.С., Абдулхаков С.Р., Шабуров Р.И., Соколов Ф.С. Распространенность гастроэзофагеальной рефлюксной болезни в России: метаанализ популяционных исследований. Терапевтический архив. 2024;96(8):751–756. [Andreev DN, Maev IV, Bordin DS, Abdulkhakov SR, Shaburov RI, Sokolov FS. Prevalence of gastroesophageal reflux disease in Russia: A meta-analysis of population-based studies. Terapevticheskiy arkhiv = Therapeutic Archive. 2024;96(8):751–756 (In Russ.)].

    EDN: CZEARJ. https://doi.org/10.26442/00403660.2024.08.202807

  4. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–43.

    PMID: 16928254. https://doi.org/10.1111/j.1572-0241.2006.00630.x

  5. Yadlapati R, Weissbrod P, Walsh E, Carroll TL, Chan WW, Gartner-Schmidt J, et al. The San Diego Consensus for laryngopharyngeal symptoms and laryngopharyngeal reflux disease. Am J Gastroenterol. 2026;121(2):322–36.

    PMID: 40197644. https://doi.org/10.14309/ajg.0000000000003482

  6. Lechien JR, Vaezi MF, Chan WW, Allen JE, Karkos PD, Saussez S, et al. The Dubai definition and diagnostic criteria of laryngopharyngeal reflux: The IFOS Consensus. Laryngoscope. 2024;134(4):1614–24.

    PMID: 37929860. https://doi.org/10.1002/lary.31134

  7. Lechien JR, Akst LM, Saussez S, Crevier-Buchman L, Hans S, Barillari MR, et al. Involvement of laryngopharyngeal reflux in select nonfunctional laryngeal diseases: A systematic review. Otolaryngol Head Neck Surg. 2021;164(1):37–48.

    PMID: 32571152. https://doi.org/10.1177/0194599820933209

  8. Spantideas N, Drosou E, Karatsis A, Assimakopoulos D. Voice disorders in the general Greek population and in patients with laryngopharyngeal reflux. Prevalence and risk factors. J Voice. 2015;29(3):389.e27–389.e3.89E32.

    PMID: 25795358. https://doi.org/10.1016/j.jvoice.2014.08.006

  9. Xiao S, Li J, Zheng H, Yan Y, Li X, Zhang L, et al. An epidemiological survey of laryngopharyngeal reflux disease at the otorhinolaryngology-head and neck surgery clinics in China. Eur Arch Otorhinolaryngol. 2020;277(10):2829–38.

    PMID: 32449029. https://doi.org/10.1007/s00405-020-06045-0

  10. Ruiz R, Jeswani S, Andrews K, Rafii B, Paul BC, Branski RC, Amin MR. Hoarseness and laryngopharyngeal reflux: A survey of primary care physician practice patterns. JAMA Otolaryngol Head Neck Surg. 2014;140(3):192–96.

    PMID: 24481258. https://doi.org/10.1001/jamaoto.2013.6533

  11. Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108(6):905–11.

    PMID: 23545710. https://doi.org/10.1038/ajg.2013.69

  12. Yadlapati R, Weissbrod P, Walsh E, Carroll TL, Chan WW, Gartner-Schmidt J, et al. The San Diego Consensus for laryngopharyngeal symptoms and laryngopharyngeal reflux disease. Am J Gastroenterol. 2026;121(2):322–36.

    PMID: 40197644. https://doi.org/10.14309/ajg.0000000000003482

  13. Chen JW, Vela MF, Peterson KA, Carlson DA. AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: Expert review. Clin Gastroenterol Hepatol. 2023;21(6):1414–21.e3.

    PMID: 37061897. https://doi.org/10.1016/j.cgh.2023.01.040

  14. Gyawali CP, Roman S, Zerbib F, Savarino EV, Bhatia S, Fass R, Pandolfino JE. Functional esophageal disorders. Gastroenterology. 2026;170(6):1224–39.

    PMID: 42031441. https://doi.org/10.1053/j.gastro.2026.02.005

  15. Maev IV, Livzan MA, Mozgovoi SI, Gaus OV, Bordin DS. Esophageal mucosal resistance in reflux esophagitis: What we have learned so far and what remains to be learned. Diagnostics. 2023;13(16):2664.

    PMID: 37627923. https://doi.org/10.3390/diagnostics13162664

  16. Orlando RC. Review article: Oesophageal mucosal resistance. Aliment Pharmacol Ther. 1998;12(3):191–97.

    PMID: 9570252. https://doi.org/10.1046/j.1365-2036.1998.00308.x

  17. Gunther C, Neumann H, Vieth M. Esophageal epithelial resistance. Dig Dis. 2014;32(1–2):6–10.

    PMID: 24603373. https://doi.org/10.1159/000357001

  18. Ustaoglu A, Woodland P. Sensory phenotype of the oesophageal mucosa in gastro-oesophageal reflux disease. Int J Mol Sci. 2023;24(3):2502.

    PMID: 36768825. https://doi.org/10.3390/ijms24032502

  19. Gyawali CP, Yadlapati R, Fass R, Katzka D, Pandolfino J, Savarino E, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024;73(2):361–71.

    PMID: 37734911. https://doi.org/10.1136/gutjnl-2023-330616

  20. Li Y, Xu G, Zhou B, Tang Y, Liu X, Wu Y, et al. Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: Physiopathology and therapeutic targets. Eur Arch Otorhinolaryngol. 2022;279(6):2743–52.

    PMID: 34860271. https://doi.org/10.1007/s00405-021-07201-w

  21. Cui N, Dai T, Liu Y, Wang YY, Lin JY, Zheng QF, et al. Laryngopharyngeal reflux disease: Updated examination of mechanisms, pathophysiology, treatment, and association with gastroesophageal reflux disease. World J Gastroenterol. 2024;30(16):2209–19.

    PMID: 38690022. https://doi.org/10.3748/wjg.v30.i16.2209

  22. Haq AU. Extra-esophageal manifestations of gastroesophageal reflux disease in adults: A scoping review. J Univ Coll Med Dent. 2026;5(2):180–87.

    https://doi.org/10.51846/jucmd.v5i2.5440

  23. Lechien JR, Chebib E, De Marrez LG, Hans S. Laryngopharyngeal symptoms are insufficient to diagnose laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2022;279(10):5055–56.

    PMID: 34378056. https://doi.org/10.1007/s00405-021-07034-7

  24. Jaworek AJ, Carroll TL. Chronic cough and pulmonary manifestations of laryngopharyngeal reflux disease. Otolaryngol Clin North Am. 2025;58(3):485–96.

    PMID: 40148169. https://doi.org/10.1016/j.otc.2025.01.004

  25. Chan WW, Myers JC, Carroll TL, Misono S, Chen CL, Coss-Adame E, et al.; San Diego Consensus Working Group. Laryngopharyngeal symptoms and laryngopharyngeal reflux disease: Presentation, health care burden, and risk stratification. Neurogastroenterol Motil. 2026;38(5):e70339.

    PMID: 42108738. https://doi.org/10.1111/nmo.70339

  26. Pineda Ovalle LF, Salcedo V, Rodríguez Orjuela AP, Mora Leon CA, Gomez Rodríguez A, Moya Valenzuela L, Paramo Hernandez D. Clinical predictors of pathological gastroesophageal reflux: A pH-impedance study of 2688 adults with laryngopharyngeal reflux symptoms. Dis Esophagus. 2026;39(4):doag089.

    PMID: 42585563. https://doi.org/10.1093/dote/doag089

  27. Frazzoni M, Savarino E, de Bortoli N, Martinucci I, Furnari M, Frazzoni L, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. Clin Gastroenterol Hepatol. 2016;14(1):40–46.

    PMID: 26122764. https://doi.org/10.1016/j.cgh.2015.06.026

  28. Siboni S, Sozzi M, Visaggi P, De Maron R, Asti E. New tools for the grading and scoring of gastro-esophageal reflux disease. Rev Gastroenterol Mex (Engl Ed). 2025;90(3):412–27.

    PMID: 40935735. https://doi.org/10.1016/j.rgmxen.2025.09.005

  29. Siboni S, Sozzi M, Visaggi P, Boveri S, Rogers BD, De Bortoli N, et al. Combined Lyon and Milan Scores predict GERD management outcome better than Either Score alone or their individual components. Aliment Pharmacol Ther. 2025;62(7):710–21.

    PMID: 40541561. PMCID: PMC12422723. https://doi.org/10.1111/apt.70245

  30. Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, Lind T. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030–38.

    PMID: 19737151. https://doi.org/10.1111/j.1365-2036.2009.04142.x

  31. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16(2):274–77.

    PMID: 12150380. https://doi.org/10.1016/s0892-1997(02)00097-8

  32. Lechien JR, Huet K, Finck C, Khalife M, Fourneau AF, Delvaux V, et al. Validity and reliability of a French version of Reflux Symptom Index. J Voice. 2017;31(4):512.e1–512.e7.

    PMID: 28069467. https://doi.org/10.1016/j.jvoice.2016.11.020

  33. Carrau RL, Khidr A, Gold KF, Crawley JA, Hillson EM, Koufman JA, Pashos CL. Validation of a quality-of-life instrument for laryngopharyngeal reflux. Arch Otolaryngol Head Neck Surg. 2005;131(4):315–20.

    PMID: 15837899. https://doi.org/10.1001/archotol.131.4.315

  34. Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice. 2002;16(4):564–79.

    PMID: 12512644. https://doi.org/10.1016/s0892-1997(02)00132-7

  35. Chan WW, Schroeder M, Richardson A, Shah N, Muftah M, Muftah S, et al.; Milan Score Working Group. Validation of esophageal global symptom severity as a patient-reported outcome for evaluation of reflux symptoms. Am J Gastroenterol. 2025;120(8):1760–69.

    PMID: 40267269. PMCID: PMC12316544. https://doi.org/10.14309/ajg.0000000000003499

  36. Krause AJ, Carlson DA, Chan WW, Chen CL, Gyawali CP; Laryngeal Symptoms Working Group; Yadlapati R. High diagnostic yield of abnormal endoscopic findings in the evaluation of laryngopharyngeal reflux. Clin Gastroenterol Hepatol. 2024;22(8):1741–43.e1.

    PMID: 38278193. PMCID: PMC11266523. https://doi.org/10.1016/j.cgh.2024.01.012

  37. Herregods TVK, Pauwels A, Tack J, Smout AJPM, Bredenoord AJ. Reflux-cough syndrome: Assessment of temporal association between reflux episodes and cough bursts. Neurogastroenterol Motil. 2017;29(12).

    PMID: 28612466. https://doi.org/10.1111/nmo.13129

  38. Siboni S, Sozzi M, Visaggi P, Kristo I, De Bortoli N, Tolone S, et al. The Milan Score is an effective manometric tool to predict gastroesophageal reflux in patients with laryngopharyngeal symptoms. Neurogastroenterol Motil. 2026;38(4):e70015.

    PMID: 40317611. PMCID: PMC13121873. https://doi.org/10.1111/nmo.70015

  39. Dy F, Amirault J, Mitchell PD, Rosen R. Salivary pepsin lacks sensitivity as a diagnostic tool to evaluate extraesophageal reflux disease. J Pediatr. 2016;177:53–58.

    PMID: 27453366. PMCID: PMC5037022. https://doi.org/10.1016/j.jpeds.2016.06.033

  40. Zhang M, Pandolfino JE, Zhou X, Tan N, Li Y, Chen M, Xiao Y. Assessing different diagnostic tests for gastroesophageal reflux disease: A systematic review and network meta-analysis. Ther Adv Gastroenterol. 2019;12:1756284819890537.

    PMID: 31803253. PMCID: PMC6876191. https://doi.org/10.1177/1756284819890537

  41. De Vos NV, Trelcat A, Antoine M, et al. Performance study of noninvasive salivary biomarkers in laryngopharyngeal reflux. J Appl Lab Med. 2026;11(2):307–19.

    PMID: 41283896. https://doi.org/10.1093/jalm/jfaf171

  42. Ивашкин В.Т., Трухманов А.С., Маев И.В., Драпкина О.М., Ливзан М.А., Мартынов А.И. с соавт. Диагностика и лечение гастроэзофагеальной рефлюксной болезни (Рекомендации Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Научного сообщества по изучению микробиома человека). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(5):111–135. [Ivashkin VT, Trukhmanov AS, Maev IV, Drapkina OM, Livzan MA, Martynov AI, et al. Diagnosis and treatment of gastroesophageal reflux disease (clinical guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Сommunity for Human Microbiome Research). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–135 (In Russ.)].

    EDN: BPZIFZ. https://doi.org/10.22416/1382-4376-2024-34-5-111-135

  43. Patel DA, Blanco M, Vaezi MF. Laryngopharyngeal reflux and functional laryngeal disorder: Perspective and common practice of the general gastroenterologist. Gastroenterol Hepatol (N Y). 2018;14(9):512–20. PMID: 30364386. PMCID: PMC6194652.
  44. O’Hara J, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, et al. Use of proton pump inhibitors to treat persistent throat symptoms: Multicentre, double blind, randomised, placebo controlled trial. BMJ. 2021;372:m4903.

    PMID: 33414239. PMCID: PMC7789994. https://doi.org/10.1136/bmj.m4903

  45. Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302–18.

    PMID: 28827081. https://doi.org/10.1053/j.gastro.2017.07.049

  46. Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of gastroesophageal reflux disease: Where Rome, Lyon, and Montreal meet. Clin Gastroenterol Hepatol. 2020;18(4):767–76.

    PMID: 31319183. https://doi.org/10.1016/j.cgh.2019.07.015

  47. Wang B, Mei X, Guo X. Factors influencing poor response to proton pump inhibitor therapy in patients with laryngopharyngeal reflux disease and development of a clinical-voice integrated predictive model. Ear Nose Throat J. 2026:1455613261461950. Online ahead of print.

    PMID: 42313486. https://doi.org/10.1177/01455613261461950

  48. Трухманов А.С., Румянцева Д.Е. Калий-конкурентные блокаторы кислотной продукции: новые возможности антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2025;35(4):18–26. [Trukhmanov AS, Rumyantseva DE. Potassium-competitive acid blockers: New opportunities of antisecretory therapy in gastroesophageal reflux disease. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2025;35(4):18–26 (In Russ.)].

    EDN: XJYHOJ. https://doi.org/10.22416/1382-4376-2025-35-4-18-26

  49. Ливзан М.А., Гаус О.В., Мозговой С.И., Бордин Д.С., Гавриленко Д.А. Гастроэзофагеальная рефлюксная болезнь: как оптимизировать ведение больных? РМЖ. Медицинское обозрение. 2024;8(5):274–280 [Livzan MA, Gaus OV, Mozgovoy SI, Bordin DS, Gavrilenko DA. Gastroesophageal reflux disease: How to optimize patient management? Russkiy medtsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Inquiry. 2024;8(5):274–280 (In Russ.)].

    EDN: ECJOCY. https://doi.org/10.32364/2587-6821-2024-8-5-5

  50. Jin Y, Zhu M, Zhu L, Lin H. Effects of proton pump inhibitors plus gastroprokinetic agents on laryngopharyngeal reflux disease and factors influencing prognosis. Am J Transl Res. 2026;18(7):5623–31.

    PMID: 42630514. https://doi.org/10.62347/QJBI9677

  51. Bordin DS, Livzan MA, Mozgovoi SI, Gaus OV, Lapteva IV. The mucosal protection in the treatment of erosive reflux esophagitis: Mechanisms for restoring epithelial permeability. A randomized clinical trial. J Gastrointestin Liver Dis. 2024;33(4):455–62.

    PMID: 39733305. https://doi.org/10.15403/jgld-5859

  52. Матошина И.В., Ливзан М.А., Федорин М.М., Лаптева И.В. Клинически значимые стигмы выраженности ГЭРБ и диссоциация со степенью повреждения слизистой пищевода – обязательность эзофагопротекции? Экспериментальная и клиническая гастроэнтерология. 2021;190(6):5–11. [Matoshina IV, Livzan MA, Fedorin MM, Lapteva IV. Clinically significant stigmas of the severity of GERD and dissociation with the degree of damage to the esophageal mucosa – the obligatory esophagoprotection? Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021;190(6):5–11 (In Russ.)].

    EDN: ITGWYB. https://doi.org/10.31146/1682-8658-ecg-190-6-5-11

  53. Scarpignato C, De Bortoli N, Iovino P, Nacci A, Sarnelli G, Savarino EV. Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD. Ther Adv Gastroenterol. 2025;18:17562848251337822.

    PMID: 40520453. PMCID: PMC12163284. https://doi.org/10.1177/17562848251337822

  54. Матошина И.В., Федорин М.М., Ливзан М.А., Мозговой C.И. Резистентность слизистой оболочки пищевода у больных ГЭРБ: диалог клинициста и морфолога. Эффективная фармакотерапия. 2021;17(4):34–39. [Matoshina IV, Fedorin MM, Livzan MA, Mozgovoy SI. Resistance of the esophageal mucosa in patients with GERD: A dialogue between a clinician and a morphologist. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2021;17(4):34–39 (In Russ.)].

    https://doi.org/10.33978/2307-3586-2021-17-4-34-39

  55. Бордин Д.С., Андреев Д.Н., Маев И.В. Эффективность эзофагопротекции в комплексном лечении эрозивной формы гастроэзофагеальной рефлюксной болезни: систематический обзор и метаанализ контролируемых исследований. Терапевтический архив. 2022;94(12):1407–1412. [Bordin DS, Andreev DN, Maev IV. Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: A systematic review and meta-analysis of controlled trials. Terapevticheskiy arkhiv = Therapeutic Archive. 2022;94(12):1407–1412 (In Russ.)].

    EDN: KIZTWE. https://doi.org/10.26442/00403660.2022.12.202011

  56. Palmieri B, Merighi A, Corbascio D, Rottigni V, Fistetto G, Esposito A. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17(24):3272–78. PMID: 24379055.
  57. Savarino V, Pace F, Scarpignato C; Esoxx Study Group. Randomised clinical trial: Mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease – efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–42.

    PMID: 28116754. PMCID: PMC5347926. https://doi.org/10.1111/apt.13914

  58. Кучерявый Ю.А., Андреев Д.Н., Еремина Е.Ю., Гильманов А.А., Назарова О.В., Сиднева Е.А., Топалова Ю.Г. Эффективность эзофагопротектора в лечении гастроэзофагеальной рефлюксной болезни с внепищеводной симптоматикой: результаты открытого наблюдательного многоцентрового исследования. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):38–49. [Kucheryavy YuA, Andreyev DN, Eryomina EYu, Gilmanov AA, Nazarova OV, Sidneva YeA, Topalova YuG. Efficacy of esophageal protector in treating gastroesophageal reflux disease with extraesophageal symptoms: A multicenter, open-label, observational study. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):38–49 (In Russ.)]

    EDN: OUIIEG. https://doi.org/10.22416/1382-4376-2022-32-4-38-49

About the Authors

Maria A. Livzan, MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, rector and head of the Department of faculty therapy and gastroenterology, Omsk State Medical University, Omsk, Russian Federation.
E-mail: mlivzan@yandex.ru
ORCID: https://orcid.org/0000-0002-6581-7017. Scopus ID: 24341682600. eLibrary SPIN: 1961-4082
Olga V. Gaus, MD, Dr. Sci. (Medicine), associate professor, professor of the Department of faculty therapy and gastroenterology, Omsk State Medical University, Omsk, Russian Federation.
E-mail: gaus_olga@bk.ru
ORCID: https://orcid.org/0000-0001-9370-4768. Scopus ID: 56598554900. eLibrary SPIN: 7116-8419

Similar Articles